Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 4/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 2/20 | 0.44 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.44 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18681384 | 0.84 | ATM (0.45) | ATMCTSKCTSLCTSBCTSS | |
| SCHEMBL7863246 | 0.80 | ATM (0.50) | ATMCTSKCTSLCTSBCTSS | |
| SCHEMBL20647911 | 0.79 | TDP1 (0.50) | LMNAKMT2A | |
| SCHEMBL8087046 | 0.76 | KDM4C (0.54) | ATMCTSKCTSLCTSBCTSS | |
| SCHEMBL30946598 | 0.75 | CTSK (0.61) | ATMCTSKCTSLCTSBCTSS | |
| SCHEMBL241565 | 0.75 | CTSK (0.61) | ATMCTSKCTSLCTSBCTSS | |
| SCHEMBL15080869 | 0.75 | CTSK (0.61) | ATMCTSKCTSLCTSBCTSS | |
| SCHEMBL241564 | 0.75 | CTSK (0.61) | ATMCTSKCTSLCTSBCTSS | |
| SCHEMBL856196 | 0.75 | CTSK (0.61) | ATMCTSKCTSLCTSBCTSS | |
| SCHEMBL27752931 | 0.74 | POLB (0.57) | ATMCTSKCTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160075724-A1 | CETP Inhibitors | MERCK SHARP & DOHME (US) | 2016-03-17 | — | — | US | disclosed |
| US-20140221383-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221383-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8735435-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735435-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-1765793-B1 | ANACETRAPIB AND OTHER CETP INHIBITPRS | MERCK SHARP & DOHME (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2415759-A1 | CETP inhibitors | Merck Sharp & Dohme Corporation (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20100273835-A1 | NOVEL COMPOUNDS | PROBIODRUG AG (DE) | 2010-10-28 | — | — | US | disclosed |
| US-20100273835-A1 | NOVEL COMPOUNDS | PROBIODRUG AG (DE) | 2010-10-28 | — | — | US | disclosed |
| US-20100099716-A1 | CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-22 | — | — | US | disclosed |
| US-7652049-B2 | 1-benzyl-4-[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]imidazolidin-2-one; cholesteryl ester transfer protein inhibitor; raising HDL-cholesterol, reducing LDL-cholesterol; atherosclerosis; antiinflammatory agent; synergistic mixture with other active ingredients | MERCK & CO., INC. (US) | 2010-01-26 | — | — | US | disclosed |
| WO-2009007415-A2 | NOVEL COMPOUNDS | PROBIODRUG AG (DE) | 2009-01-15 | — | — | WO | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221383-A1 | CETP INHIBITORS | CETP, APOB, MTTP | ATM 1904/4885CTSK 318/4885CTSL 608/4885 |
| US-20100273835-A1 | NOVEL COMPOUNDS | IL6, PREP, PEPD | ATM 4796/4885CTSK 118/4885CTSL 23/4885 |
| US-20080119476-A1 | Cetp Inhibitors | CETP, APOB, MTTP | ATM 1904/4885CTSK 318/4885CTSL 608/4885 |
| US-20100099716-A1 | CETP INHIBITORS | CETP, APOB, MTTP | ATM 1904/4885CTSK 318/4885CTSL 608/4885 |
| US-20160075724-A1 | CETP Inhibitors | CETP, APOB, MTTP | ATM 1904/4885CTSK 318/4885CTSL 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.